Brief
Semaglutide linked to fewer asthma attacks and COPD flare-ups in real-world study
A large real-world study linked semaglutide, the drug in Ozempic and Wegovy, to nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups. Researchers say clinical trials are needed to confirm the findings.
Semaglutide, the drug sold as Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. The same study associated it with about 20% fewer COPD flare-ups.
Researchers say GLP-1 drugs may offer respiratory benefits on top of their effects on diabetes and obesity. They caution that clinical trials are needed to confirm the findings, so the link is not yet proof that semaglutide causes the drop.
Our reading
Our reading is that this is an association from real-world data rather than proof of cause, making it a promising signal that still awaits trial confirmation.
What to do or watch
Watch for clinical trials that test whether semaglutide itself reduces asthma attacks and COPD flare-ups. The precise unresolved question is whether the nearly 40% and about 20% fewer events in the real-world study reflect a true causal effect or some other factor.
Source details and supporting facts
Each line is stated by the page named above it.
Stated by sciencedaily.com
- Semaglutide is the drug found in Ozempic and Wegovy.
- Semaglutide was linked to nearly 40% fewer asthma attacks in a large real-world study.
- Semaglutide was associated with about 20% fewer COPD flare-ups.
- Researchers say clinical trials are needed to confirm the findings.
Sources
- ScienceDailyText stored 14 September 2026
How this story was checked. Written from the 1 page listed above, stored 14 September 2026; claims checked against that stored text on 14 September 2026.
What that means
- 4 of 4 reported statements were confirmed against the page that carries them; the rest were removed rather than published.
- Figures in the text were required to appear in the stored source text: yes. Identifiers: yes.
- The check reads stored text only: no claim rests on a fresh look that did not happen.
- Where the reporting was silent, the text says so instead of filling the gap.